BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis

NCT00001789 | Completed Phase 2

• 2 other identifiers: 99013399-AR-0133
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to investigate whether the experimental drug BG9588 can be used to treat lupus nephritis more effectively and with less toxicity than standard treatments, including cyclophosphamide (Cytoxan), azothioprine (Imuran) and prednisone. The body's immune system naturally produces antibodies to fight foreign substances like bacteria and viruses. In autoimmune diseases like lupus, however, the body makes antibodies that attack its own tissues, causing inflammation and organ damage. Lupus antibodies attack and damage kidney cells. BG9588 can interfere with the production of these antibodies, and therefore, may lessen kidney damage in people with lupus nephritis. This study will look at: how BG9588 enters and leaves the blood and body tissue over time; adverse effects of the drug; and whether treatment with BG9588 can result in less kidney damage than other therapies. Study patients will be receive a 30-minute infusion of BG9588 into a vein every two weeks for three doses and then once every 28 days for four doses. Patients' steroid dosage may be tapered; individual adjustments will be made as required. Patients screened for the study will undergo a physical examination, medical history, various blood and urine tests, as well as complete a quality of life questionnaire. Results of a previous kidney biopsy and chest X ray are also required. Many of these tests will be repeated throughout the study. In a previous animal study, BG9588 treatment of mice with lupus nephritis improved their disease and survival.

Conditions

Glomerulonephritis, Membranoproliferative; Lupus Nephritis

Keywords

Autoantibody; Autoimmunity; Inflammation; Kidney; Lymphocyte; Proliferative Lupus Glomerulonephritis; SLE-GN

Interventions

BG9588 DRUG

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

Must give written informed consent prior to any testing under this protocol. Must be 18 years or older, inclusive, at the time of informed consent. Must have a renal biopsy showing active WHO Class III, IV, or mixed membranous and proliferative SLE GN, within the 5 years prior to the first dose of study drug. Must have proteinuria of greater than or equal to 1.0 g/day at both the Day-27 and day-13 evaluations. Must fulfill any one the following four criteria, at each of the two screening visits (i.e., Day-27 and Day-13): Anti-dsDNA antibody greater than 2x the upper limit of normal (ULN). C3 complement less than 80 mg/dL. Hematuria greater than 5 rbc/hpf. Urinary granular or red blood cell casts. Must not have any medical disorder, which in the opinion of the investigator, should exclude the subject from this study. Must not have prior arterial or venous thrombosis, or history of recurrent abortion (3 or more), in the presence of anti-cardiolipin antibodies. Must not have a chest x-ray with evidence of active infection or neoplasm within the 6 months prior to the first dose of study drug. Must not have rapidly progressive glomerulonephritis, defined as a doubling of serum creatinine, within the 3 months prior to the first dose of study drug. Must not have fibrinoid necrosis and/or cellular crescents affecting more than 25 percent of glomeruli in any renal biopsy performed within the 3 months prior to the first dose of study drug. Must not have clinically significant findings for any of the following within the 4 weeks prior to the first dose of study drug: active psychiatric disease, serum creatinine greater than 2.0 mg/dL, prothrombin time (PT) greater than 1.3x control (in the absence of coumadin therapy; abnormal PT values due to anti-coagulation therapy are allowed if within the therapeutic range), AST or ALT levels greater than 3x normal, other major organ dysfunction, or serious local or systemic infection (e.g., pneumonia, septicemia). Must not be positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HVC Ab), or HIV antibody at the Day-27 evaluation. Must not have a mean CD4 count less than or equal to 300 microliters (mean of Day-27 and Day-13 results). Must not have treatment with an antibody or other investigational drug within the 3 months prior to the first dose of the study drug. Must not have any vaccination within the 4 weeks prior to the first dose of the study drug. Must not have treatment with IV or oral cyclophosphamide within the 4 weeks prior to the first dose of the study drug. Must not have treatment with any of the following medications within the 4 weeks prior to the first dose of study drug: IV methylprednisolone, cyclosporine or related compound, or oral prednisone (equivalent oral glucocorticoid) at a dose greater than 0.5 mg/kg/day. Must not have initiation of treatment with ACE inhibitors within the 4 weeks prior to the first dose of study drug. Must not have initiation of treatment with azathioprine, methotrexate or mycophenolate mofetil within the 4 weeks prior to the first dose of study drug. Must not have treatment with any new oral or new IV antibiotic within the 2 weeks prior to the first dose of study drug. Subjects on prophylactic antibiotics are permitted to continue these during the study. Female subjects, unless post-menopausal or surgically sterile, must use an adequate method of contraception. Women must not be currently breast-feeding. Must not have a positive pregnancy test in any evaluation prior to the first dose of study drug. Must not be currently enrolled in any other study in which the subject is receiving any type of drug or non-drug therapy. Must not have been previously dosed with BG9588.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): lead

Study Sites (1)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Bethesda, Maryland, 20892, United States

Location

Related Publications (1)

• Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Domenech I, Aydintug AO, Jedryka-Goral A, de Ramon E, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993 Mar;72(2):113-24.

  PMID: 8479324 BACKGROUND

MeSH Terms

Conditions

Glomerulonephritis, Membranoproliferative; Lupus Nephritis; Autoimmune Diseases; Inflammation

Condition Hierarchy (Ancestors)

Glomerulonephritis; Nephritis; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Immune System Diseases; Lupus Erythematosus, Systemic; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 2
• Purpose: TREATMENT
• Sponsor Type: NIH

Study Record Dates

• First Submitted: November 3, 1999
• First Posted: December 10, 2002
• Study Start: June 1, 1999
• Study Completion: May 1, 2000
• Last Updated: March 4, 2008

Record last verified: 1999-06

Locations

US (1)